The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor

2004 ◽  
Vol 113 (6) ◽  
pp. 361-369 ◽  
Author(s):  
Shanqun Jiang ◽  
Yi-Hsiang Hsu ◽  
Xin Xu ◽  
Houxun Xing ◽  
Changzhong Chen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Angiotensin Converting Enzyme ◽  
Diastolic Blood Pressure ◽  
Methylenetetrahydrofolate Reductase ◽  
Enzyme Inhibitor ◽  
Converting Enzyme ◽  
C677t Polymorphism ◽  
Reductase Gene ◽  
Methylenetetrahydrofolate Reductase Gene

scholarly journals Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study

2019 ◽  
Vol 20 (3) ◽  
pp. 147032031986889 ◽  
Author(s):  
Piotr Ruszkowski ◽  
Anna Masajtis-Zagajewska ◽  
Michał Nowicki
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Angiotensin Converting Enzyme ◽  
Endothelial Function ◽  
Enzyme Inhibitor ◽  
Converting Enzyme ◽  
C Reactive Protein ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Reactive Protein

Background: The aim of this study was to compare the influence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on endothelial function and blood pressure in patients with essential hypertension on long-term angiotensin-converting enzyme inhibitor therapy. Method: The study was designed as a prospective, double-blind, randomised, placebo controlled, crossover clinical trial. Twenty patients with essential hypertension were treated with an angiotensin-converting enzyme inhibitor; the control group included 10 healthy subjects. Hypertensive patients received in random order 80 mg of fluvastatin daily or placebo for 6 weeks. The following parameters were assessed at baseline and after each treatment period: serum lipids, flow-mediated vasodilation, activity of von Willebrand factor, concentration of vascular endothelial growth factor, C-reactive protein and 24-hour blood pressure profile. Results: Hypertensive patients did not differ from healthy subjects with respect to age, body mass and biochemical parameters, with the exception of C-reactive protein, which was higher in hypertensive patients ( P=0.02). After statin therapy, low-density lipoprotein cholesterol ( P<0.0001), C-reactive protein ( P=0.03), von Willebrand factor ( P=0.03) and vascular endothelial growth factor ( P<0.01) decreased and flow-mediated vasodilation improved ( P<0.001). Statins had no significant effect on blood pressure. Conclusions: Statins added to angiotensin-converting enzyme inhibitors may improve endothelial function and ameliorate inflammation independently of blood pressure.

Effects in Healthy Subjects of a New Non-Thiol-Containing Angiotensin-Converting Enzyme Inhibitor, Enalapril Maleate (MK-421)

1982 ◽  
Vol 63 (s8) ◽  
pp. 183s-185s ◽  
Author(s):  
Mitsuyoshi Nakashima ◽  
Kenji Nishijima
Keyword(s):  
Blood Pressure ◽  
Angiotensin Converting Enzyme ◽  
Systolic Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Enzyme Inhibitor ◽  
Plasma Concentrations ◽  
Maximum Plasma ◽  
Converting Enzyme ◽  
Enalapril Maleate ◽  
Maximum Decrease

1. Single doses of enalapril maleate, ranging from 2.5 to 20 mg, were given orally to 12 normotensive volunteers to determine tolerability, activity on the various components of the renin-angiotensin-aldosterone system and initial pharmacokinetics. 2. Enalapril was rapidly absorbed and maximum plasma concentrations of the diacid, the active metabolite of enalapril, occurred at 3–6 h after dosing. 3. Enalapril significantly decreased systolic blood pressure at 4–6 h after the drug and diastolic blood pressure at 3–6 h after the drug. The maximum decrease of systolic blood pressure was observed at 3–4 h, whereas the maximum decrease of diastolic blood pressure was observed at 6 h. 4. Plasma angiotensin-converting enzyme activity was significantly reduced at all doses. The reduction persisted through 24 h after dosage. Plasma renin activity significantly increased after doses of 5 mg and 20 mg. Aldosterone levels significantly decreased after doses of 10 mg and 20 mg. 5. There were no adverse clinical experiences or abnormal laboratory values noted.

Angiotensin converting enzyme and methylenetetrahydrofolate reductase gene variations in fibromyalgia syndrome

Gene ◽  
2015 ◽  
Vol 564 (2) ◽  
pp. 188-192 ◽  
Author(s):  
Ahmet Inanir ◽  
Serbulent Yigit ◽  
Akin Tekcan ◽  
Ferda Alpaslan Pinarli ◽  
Sema Inanir ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Fibromyalgia Syndrome ◽  
Methylenetetrahydrofolate Reductase ◽  
Converting Enzyme ◽  
Reductase Gene ◽  
Methylenetetrahydrofolate Reductase Gene
Sign in / Sign up

Export Citation Format

Share Document